Drug Manufacturers - General · NYSE
Preço Atual
$1009.00
MOAT COMPETITIVO
↑Patent Protection on Key Drugs
Lilly benefits from strong patent protection on drugs like Trulicity and Mounjaro. This exclusivity allows for premium pricing and market share dominance before generics enter.
↑Established Brand Reputation in Diabetes Care
Lilly has cultivated a strong brand in diabetes, fostering physician and patient loyalty. This reputation provides a competitive edge in a growing market.
↑Pipeline of Innovative Therapies
Lilly's robust pipeline, particularly in Alzheimer's and obesity, offers future growth potential. Successful drug launches will further solidify their market position.
RISCOS DE INVESTIMENTO
↓Patent Expirations and Generic Competition
Loss of exclusivity on key drugs will significantly impact revenue. Lilly must successfully launch new products to offset these losses and maintain growth.
↓Clinical Trial Failures and Regulatory Hurdles
Drug development is inherently risky, and clinical trial failures are common. Regulatory delays or rejections can significantly impact pipeline value.
↓Pricing Pressure and Reimbursement Challenges
Increasing pressure from payers to lower drug prices could erode profitability. Changes in reimbursement policies could limit access to Lilly's therapies.
Combine insights de IA com valuation DCF ou PE para calcular o valor intrínseco. Tome decisões melhores baseadas em dados.
Esta página fornece insights de valuation com IA para Eli Lilly and Company (LLY), incluindo moat competitivo e fatores de risco de investimento. O valuation é central para decisões de investimento sólidas — use as ferramentas de valuation DCF e PE do MiniValuator junto com estes insights de IA para calcular o valor intrínseco de LLY, margem de segurança, e chegar a um valuation bem fundamentado.
